SARS-CoV-2 and COVID-19 Research

This study analyzes the mutation and evolutionary dynamics of SARS-CoV-2 variants of concern in India from 2020 to 2023, identifying key mutations and their structural impacts.

This study identifies non-neutralizing antibodies from vaccinated individuals that protect against SARS-CoV-2 in animal models, highlighting their role through Fc-mediated effector functions and conserved epitope binding.

This study identifies TMEM106B as a key mediator of ACE2-independent SARS-CoV-2 infection in vitro but shows no in vivo neuroinvasiveness or respiratory tract replication in mice.

This study analyzes C->U transition biases in SARS-CoV-2 genomes over four years, finding a consistent rate of C base loss and U accumulation, with most substitutions occurring at non-random sites.

This study shows that combining intramuscular mRNA priming with intranasal protein boosting using a combination adjuvant enhances mucosal B- and T-cell responses against SARS-CoV-2 compared to other vaccination regimens.

This paper develops a method to engineer customized viral receptors (CVRs) for various coronaviruses, enabling infection models for viruses lacking known receptors.

This study finds that BCR repertoire diversity, not TCR diversity, correlates with favorable outcomes in COVID-19 patients.

This study identifies cross-reactive antibodies against SARS-CoV-2 and related sarbecoviruses that target conserved epitopes and show broad neutralization potential.

This study examines how SARS-CoV-2 booster vaccines affect antibody profiles in myeloma patients, finding improved binding but not neutralization against variants.

This study analyzes SARS-CoV-2 spike protein mutations in Bangladesh and finds no significant association with clinical outcomes, though age and gender influence recovery and symptom severity.

The paper characterizes the CAST/EiJ mouse strain as a model for severe COVID-19 by showing it develops high viral burdens, severe lung pathology, and cytokine dysregulation leading to mortality.

The paper shows that Nirmatrelvir-resistant mutations in SARS-CoV-2 Mpro enhance immune evasion by cleaving NEMO, leading to reduced immune response and improved viral replication.

This paper uses molecular dynamics simulations to show that heparan sulfate and N-glycans stabilize the SARS-CoV-2 spike:ACE2 complex and promote viral entry by triggering structural changes.

This study identifies RBM indel types in sarbecoviruses and their impact on ACE2 receptor usage across species, revealing how specific residues and structural features influence tropism and adaptiveness.

The paper shows that B cells from ancestral SARS-CoV-2 infections can develop broad neutralization against multiple sarbecoviruses after repeated immune challenges.

This paper develops a single domain antibody targeting ACE2 that protects against SARS-CoV-2 infection in mice when delivered intranasally.

This study identifies linear B-cell epitopes against human coronaviruses using pooled sera from COVID-19 convalescents and pre-pandemic controls, revealing cross-reactivity patterns and epitope distribution across coronavirus proteins.

This paper presents a method to sequence polyclonal IgG antibodies from human plasma post-SARS-CoV-2 vaccination, generating recombinant antibodies with neutralizing capabilities.

This study shows that mutating a conserved isoleucine in the macrodomain of MERS-CoV and SARS-CoV-2 enhances ADP-ribose binding but reduces viral replication and pathogenesis.

This study investigates the differential clearance rates of spike protein and replicase components from a self-amplifying mRNA vaccine in muscle and lymph nodes, linking prolonged expression in lymph nodes to sustained antibody levels.

The paper uses hamster sera to map antigenic differences among SARS-CoV-2 variants, showing JN.1 has significant antigenic divergence from XBB.1.5.

This study evaluates the MD+FoldX method's ability to predict SARS-CoV-2 antibody escape mutations using a large deep mutational scanning dataset, showing moderate correlation with experimental data.

The paper investigates how Omicron-specific naive B cell maturation after breakthrough infection alleviates immune imprinting from inactivated SARS-CoV-2 vaccines.

This study identifies ultra-potent Omicron-specific antibodies targeting the N1/N2 loop of the Spike NTD, which neutralize SARS-CoV-2 by competing with ACE2 and blocking S1 shedding, but are evaded by BA.2.86 and BA.2.87.1 sublineages.

The paper describes the engineering of synthetic multivalent VHH antibodies against SARS-CoV-2 spike protein and shows how mutations affect their binding.

This study evaluates the virological characteristics of BA.5.2.48 subvariant isolates, finding enhanced transmission and pathogenicity compared to BA.2, with divergent features among subvariants.

The paper evaluates the neutralization activity of two new monoclonal antibodies against emerging SARS-CoV-2 variants and finds reduced efficacy against some sublineages.

This study enhances the affinity of SARS-CoV-2 neutralizing nanobodies through structure-guided mutations in CDRs, resulting in improved neutralization activity against pseudovirus.

The paper identifies a pan-betacoronavirus antibody that binds the S2 subunit of spike proteins and induces Fc-dependent antiviral responses, offering insights into non-neutralizing antibody protection.